Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

38%

3 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

4(50.0%)

Phase 3

3(37.5%)

Phase 2

1(12.5%)

8Total

Phase 1(4)

Phase 3(3)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06585696Phase 3Completed

A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection (CU-20101)

Role: lead

NCT06744569Phase 1Enrolling By Invitation

A Phase I Clinical Trial to Evaluate CU-10101 Unguent

Role: lead

NCT06194188Phase 2Completed

A Phase 2 Clinical Study of CU-20401

Role: lead

NCT05173883Phase 1Completed

A Phase 1 Clinical Study of CU-20401 in Chinese Healthy Population

Role: lead

NCT05195541Phase 1Completed

A Clinical Study to Evaluate the Safety, Pharmacokinetic Profile and Efficacy of CU-20401

Role: lead

NCT05793892Phase 3Completed

Efficacy and Safety of Lidocaine and Tetracaine Cream for Facial Laser Aesthetics in Chinese Adults

Role: lead

NCT05380427Phase 1Completed

A Phase I Clinical Trial Evaluating the Safety, Tolerability, and Pharmacokinetics of CU-40101 Liniment in Single and Multiple Doses in Adult Male Androgenic Alopecia Subjects

Role: lead

NCT05135468Phase 3Completed

A Phase 3 Clinical Study Patients With Androgenetic Alopecia (AGA)

Role: lead

All 8 trials loaded